Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 1,870 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BE-FAST Clear all
Completed Phase 2 Interventional Results available

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

NCT02702388
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Lenvatinib matching placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 13, 2026, 1:05 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Apnea in Elderly

NCT02703220
View directory record Official record
Conditions
Sleep Apnea, Elderly Adults
Interventions
Hyperoxia/oxygen, Acetazolamide, Finasteride
Other · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 13, 2026, 1:05 AM EST
Completed Not applicable Interventional Results available

A Multi-Center Study of Reading Rehabilitation in Macular Disease

NCT00746668
View directory record Official record
Conditions
Age Related Maculopathy, Retinal Degeneration
Interventions
Module 1: Visual Awareness and Eccentric Viewing, Module 2: Control of Reading Eye Movements, Module 3: Reading Practice with RSVP
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Nov 13, 2026, 1:05 AM EST
Active, not recruiting Phase 1 Interventional

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

NCT05944562
View directory record Official record
Conditions
Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome
Interventions
Tulmimetostat
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 13, 2026, 1:05 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

NCT02244827
View directory record Official record
Conditions
Hepatic Impairment
Interventions
WCK 2349
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Nov 13, 2026, 1:05 AM EST
Not listed No phase listed Observational

Automated Detection and Triage of Large Vessel Occlusions Using Artificial Intelligence for Early and Rapid Treatment (ALERT)

NCT04142879
View directory record Official record
Conditions
Stroke Workflow and Clinical Outcome Parameters
Interventions
Viz Device Software
Device
Lead sponsor
Providence Little Company of Mary-Torrance
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Nov 13, 2026, 1:05 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain

NCT06968689
View directory record Official record
Conditions
Pain
Interventions
transcranial alternating current stimulation (tACS), Sham, transcranial random noise stimulation (tRNS)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 13, 2026, 1:05 AM EST
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 13, 2026, 1:05 AM EST
Not listed Phase 4 Interventional

Rapid Atrial Fibrillation Treatment Strategy

NCT04092621
View directory record Official record
Conditions
New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
Interventions
Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy
Drug · Procedure
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Nov 13, 2026, 1:05 AM EST
Completed Phase 1 Interventional Results available

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

NCT00422097
View directory record Official record
Conditions
Cancer
Interventions
Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Nov 13, 2026, 1:05 AM EST
Completed No phase listed Observational

Using Rapid Cycle Trials to Increase Patient Engagement in the Community Health Worker Program in the Emergency Department

NCT03455465
View directory record Official record
Conditions
Patient Engagement; Community Health Workers
Interventions
Community Health Worker Assessment
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
2,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Nov 13, 2026, 1:05 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

NCT05277012
View directory record Official record
Conditions
Healthy Participants
Interventions
Etrumadenant
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Nov 13, 2026, 1:05 AM EST
Terminated Phase 2 Interventional Results available

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib 150 mg, Trametinib 2.0 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Nov 13, 2026, 1:05 AM EST
Terminated Not applicable Interventional

RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease

NCT03365531
View directory record Official record
Conditions
NAFLD, Obesity, Diabetes Mellitus, Type 2
Interventions
Alternate Daily Fasting (ADF), Caloric Restriction (CR)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Nov 13, 2026, 1:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Daily Calorie or Alternate-day Calorie Reductions on Risk for Cardiovascular Disease and Cancer

NCT00467220
View directory record Official record
Conditions
Moderately Overweight Individuals
Interventions
calorie restriction
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Nov 13, 2026, 1:05 AM EST
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Nov 13, 2026, 1:05 AM EST
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT06636175
View directory record Official record
Conditions
Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions
64Cu-LLP2A, PET/CT
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 13, 2026, 1:05 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential

NCT04274075
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-9545 Tablet, Fasted: Treatment A, GDC-9545 Capsule, Fasted: Treatment B, GDC-9545 Capsule, Fed: Treatment C
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Nov 13, 2026, 1:05 AM EST
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 13, 2026, 1:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radio Frequency Microneedling for Suprapatellar Skin

NCT03507036
View directory record Official record
Conditions
Skin Laxity
Interventions
Profound system
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Nov 13, 2026, 1:05 AM EST
Terminated Phase 1 Interventional Results available

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

NCT01378377
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Pimasertib, Temsirolimus
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Rockland, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Nov 13, 2026, 1:05 AM EST
Completed No phase listed Observational

Body Composition Post Cancer Treatment

NCT03690401
View directory record Official record
Conditions
Cancer
Interventions
SOZO Device, DEXA Scan
Device
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Nov 13, 2026, 1:05 AM EST
Suspended Phase 1 Interventional

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

NCT04996030
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
SY-2101, Arsenic Trioxide
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Nov 13, 2026, 1:05 AM EST
Not yet recruiting Not applicable Interventional

Time-Restricted Eating and Exercise for Bone Health

NCT07824375
View directory record Official record
Conditions
Osteopenia
Interventions
Time-restricted eating combined with resistance exercise (TRE+Ex), Habitual eating pattern combined with resistance exercise (HE+Ex)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 13, 2026, 1:05 AM EST